Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

VRC01 is being evaluated in the AMP efficacy trials, the first assessment of a passively administered broadly neutralizing monoclonal antibody (bnAb) for HIV-1 prevention. A key analysis will assess serum VRC01-mediated neutralization as a potential correlate of protection. To prepare for this analy...

Full description

Bibliographic Details
Main Authors:	Yunda Huang, Lily Zhang, Amanda Eaton, Nonhlanhla N. Mkhize, Lindsay N. Carpp, Erika Rudnicki, Allan DeCamp, Michal Juraska, April Randhawa, Adrian McDermott, Julie Ledgerwood, Philip Andrew, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, John Mascola, Peter B. Gilbert, Lynn Morris, David C. Montefiori
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-01-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	population pharmacokinetic modeling pharmacokinetics/pharmacodynamics joint modeling correlates analysis monoclonal antibodies hiv-1 prevention broadly neutralizing antibody breakthrough viruses
Online Access:	http://dx.doi.org/10.1080/21645515.2021.1908030

Similar Items

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
by: Martina S. Wesley, et al.
Published: (2021-08-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults
by: Nathan John Hanan, et al.
Published: (2019-02-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
by: Patrick M. Glassman, et al.
Published: (2014-03-01)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
by: Shufang Liu, et al.
Published: (2023-12-01)

Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use
by: Melanie Grandits, et al.
Published: (2023-02-01)

Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies
by: Boris Grinshpun, et al.
Published: (2021-01-01)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01)

Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics
by: Kevin J. H. Allen, et al.
Published: (2018-12-01)

Overview of Antibody Drug Delivery
by: Sahar Awwad, et al.
Published: (2018-07-01)

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
by: Shufang Liu, et al.
Published: (2021-01-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
by: Freeman Daniel J, et al.
Published: (2012-07-01)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
by: Shun Xin Wang-Lin, et al.
Published: (2018-01-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Antibody-drug conjugates for cancer therapy
by: Anna Grzywa
Published: (2021-11-01)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
by: Andrew Lim, et al.
Published: (2023-05-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework
by: Romain Ollier, et al.
Published: (2023-12-01)

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats
by: Yero Espinoza, et al.
Published: (2019-06-01)

Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration
by: Rodney R. Walters, et al.
Published: (2021-06-01)

Characterization, pharmacokinetics, in vitro cytotoxicity of oxytetracycline-loaded CaCo₃ nanoparticle and its antibacterial and antibiofilm effects against Corynebacterium pseudotuberculosis isolated from goats
by: Banke, Idris Sherifat
Published: (2020)

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
by: Capucine Arrivé, et al.
Published: (2023-11-01)

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization
by: Aurélie Truffot, et al.
Published: (2021-12-01)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
by: Eleni Pefani, et al.
Published: (2023-04-01)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
by: Jessica Cusato, et al.
Published: (2019-01-01)

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
by: Christophe Maritaz, et al.
Published: (2022-01-01)

Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
by: Rebecca Faresjö, et al.
Published: (2021-06-01)

Pharmacokinetic study and preliminary evaluation of safety and efficacy of the recombinant human monoclonal antibodies against rabies virus (rhRIG) in Chinese healthy population: A randomized, single-blinded, placebo-controlled phase Ia clinical trial
by: Xi Chen, et al.
Published: (2023-09-01)

Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics
by: Patrice Douillard, et al.
Published: (2019-09-01)

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors
by: Christina Yacoob, et al.
Published: (2016-11-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective
by: Andrew T. Lucas, et al.
Published: (2021-07-01)

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
by: Himanshu P. Upadhyaya, et al.
Published: (2023-06-01)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
by: Victor M. Villalobos, et al.
Published: (2020-02-01)

The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models
by: Carolina Herrera
Published: (2019-05-01)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022-12-01)